CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial growth for Naveris and a strategic focus on expanding testing and improving efficiency, which are positive indicators. The high attach rate for digital solutions at transplant centers and stable reimbursement rates further support a positive outlook. However, some uncertainties, such as the GYN indication timeline and lack of Naveris contribution to current revenue guidance, temper the sentiment slightly. Overall, the positive growth projections and market leadership in key areas suggest a likely positive stock price movement.
Key Financial Performance
Total Revenue Increased 39% year-over-year to $118 million. This growth was driven by strong performance in testing services and patient digital solutions.
Testing Volume Increased 17% year-over-year to 54,900 tests. This reflects higher adoption and utilization of testing services.
Testing Services Revenue Increased 48% year-over-year to $91 million or $1,660 per test. Growth attributed to increased testing volume and higher revenue per test.
Patient Digital Solutions Revenue Increased 33% year-over-year to $16 million. Growth driven by expanded adoption of digital solutions.
Lab Products Revenue Declined 4% year-over-year to $10 million. The decline reflects a strategic shift and divestiture of the Lab Products business.
Non-GAAP Gross Margins Increased to 73%. Improvement driven by operational efficiencies and higher revenue contributions from testing services.
Non-GAAP Operating Expenses $69 million or 59% of revenue, including approximately $2 million incremental bonus accrual for performance above plan.
GAAP Net Income $3 million, reflecting improved profitability.
Adjusted EBITDA Increased over 300% year-over-year to $19 million. Growth driven by higher revenue and operational efficiencies.
Cash Collections Increased 52% year-over-year to $121 million. Reflects improved cash flow management and higher revenue.
Cash Flow from Operations $4 million for the quarter and $72 million over the last 4 quarters. Indicates strong operational cash generation.
Cash and Cash Equivalents Ended the quarter at $198 million with no debt. Reflects strong liquidity position.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AlloHeme: Advanced with clinical data from the ACROBAT study, presented at Tandem and EBMT, with publication submission anticipated in Q2 2026.
AlloSure Liver: Progressing to expand into liver transplantation, with follow-up data being gathered in the MAPLE trial to validate the solution.
HistoMap Kidney: Launch preparation ongoing, with submission of second clinical validation manuscript and advancing CLIA readiness.
VANTx: Launched as an AI-enabled clinical insights platform to aggregate and analyze molecular and clinical data for better decision-making.
Naveris Acquisition: Acquired Naveris to expand into viral-mediated cancer diagnostics, with a focus on HPV-associated cancers. Naveris has performed 130,000 commercial tests, has 2,000 active ordering physicians, and is covered for 100 million lives.
Solid Organ Transplant: Maintained leadership in heart, kidney, and lung transplantation, with liver transplantation progressing into validation.
Workflow Integration: Integrated solutions into clinical workflows with Epic Aura and Enterprise LIMS infrastructure, targeting 50% testing volume through integrated sites by year-end.
Lab Products Divestiture: Divested Lab Products business for $170 million to streamline operations and focus on core precision medicine testing services.
Portfolio Optimization: Streamlined operations by divesting Lab Products and acquiring Naveris to focus on precision medicine testing and digital solutions.
Evidence Generation: Advanced clinical utility of on-market products through studies like ALAMO, HARBOR, and MERIT to support new indications and clinical relevance.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Reimbursement Risks: The company faces potential risks related to regulatory approvals and reimbursement frameworks, particularly with the integration of Naveris' testing platform and its Medicare coverage. Any changes in reimbursement policies or regulatory hurdles could impact financial performance.
Operational Integration Challenges: The acquisition of Naveris and the divestiture of the Lab Products business present operational risks, including the integration of new teams, technologies, and workflows, as well as potential disruptions during the transition period.
Market Adoption Risks: The success of new products like AlloSure Liver and HistoMap Kidney depends on market adoption and the ability to establish these as standard care practices. Slow adoption rates could hinder revenue growth.
Economic and Competitive Pressures: The company operates in highly competitive markets, particularly in precision medicine and oncology diagnostics. Competitive pressures and economic uncertainties could impact pricing and market share.
Supply Chain and Workflow Disruptions: The company’s reliance on integrated workflows and software solutions like Epic Aura and LIMS infrastructure poses risks if there are disruptions or delays in implementation, which could affect operational efficiency and customer satisfaction.
Financial Risks from Divestiture: The divestiture of the Lab Products business could lead to financial uncertainties, including the realization of expected cash flows and the impact on overall revenue and profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Guidance: CareDx has raised its 2026 revenue guidance to a range of $447 million to $465 million, representing a 20% year-over-year increase at the midpoint of $456 million.
Adjusted EBITDA Guidance: The company projects adjusted EBITDA for 2026 to range between $43 million and $57 million, reflecting a 58% year-over-year increase at the midpoint of $50 million.
Testing Volume Projections: Testing volume is expected to range between 224,000 and 229,000 tests for 2026, representing a 13% year-over-year increase at the midpoint of 226,500 tests.
Revenue Per Test: Revenue per test is projected to increase by 10% year-over-year, with an average accrual rate per test rising from $1,405 in Q1 to $1,460 by year-end.
Lab Products Divestiture: The divestiture of the Lab Products business is expected to close by the end of Q3 2026, generating approximately $160 million in net cash proceeds. The Lab Products business is projected to contribute $45 million to $50 million in annual revenue and $3 million to $9 million in EBITDA prior to divestiture.
Naveris Acquisition: The acquisition of Naveris is expected to contribute to CareDx's growth strategy, with Naveris projected to grow its revenue by 30% to 40% annually over the next three years. The U.S. total addressable market for Naveris' offerings is estimated at $4.5 billion.
Epic Integration for Workflow Efficiency: CareDx aims to achieve approximately 50% of testing volume through Epic-integrated sites by the end of 2026, with 9 centers live and 16 additional integrations underway.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The Board of Directors authorized a common stock repurchase program of up to $100 million of shares over a period of up to 24 months.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How much of the $4.5 billion TAM for MRD is immediately accessible through existing infrastructure, and what new clinical channels are needed for the projected 30%-40% annual growth?
A:$1.5 billion of the TAM is currently accessible in the MRD space, particularly in head and neck and anal cancers. The Naveris team has already built a channel into specialty providers, so no new channels are needed. CareDx plans to accelerate revenue and volume growth through workflow optimization and Epic integration.
Q:What is the attach rate for digital solutions among high-volume transplant center customers?
A:70% of transplant centers across the U.S. use at least one CareDx patient or digital solution. The more solutions a center uses, the more embedded CareDx becomes in their workflow, leading to increased testing and revenue.
Q:How long have Naveris assets been on CareDx's radar, and what is the plan for their two labs?
A:The labs, located in Massachusetts and North Carolina, are not material at this point. CareDx will focus on automating workflows, reducing costs per test, and improving revenue cycle management. The lab strategy will be evaluated over time.
Q:What is the R&D focus for Naveris, and how will CareDx support it?
A:Naveris operates efficiently with active clinical trials and 56 publications. The R&D focus is on aid-to-diagnosis indications in head, neck, and anal cancers, as well as gynecologic indications in MRD. CareDx will invest in workflow, commercial infrastructure, and testing over the first five years post-treatment.
Q:What is the macro view on the transplant procedure environment and its impact on testing volumes?
A:Transplant procedure volumes fluctuate. Growth in testing volumes is driven by the increasing number of unique patients being tested over time, even if transplant volumes remain flat. CareDx is focused on supporting centers in the IOTA program to increase transplant volumes.
Q:What is the status of the GYN cancer indication development at Naveris?
A:The GYN indication is still in development due to the heterogeneity of HPV-driven proteins. There is no specific timeline for its launch.
Q:How many employees does Naveris have, and what is the plan for their commercial team?
A:Naveris has 100 employees. CareDx plans to support and expand the existing commercial channel to drive growth.
Q:What is the reimbursement rate for Naveris tests, and is it expected to change?
A:The reimbursement rate is $1,800 per test under ADLT status. It has been consistent, and no changes are expected.
Q:What is the timing for the LCD for transplant from the MolDx Group?
A:The LCD is expected to be finalized or retired by mid-2026, as CMS typically adheres to a one-year timeline from the draft issuance date.
Q:What operational learnings from the transplant business can be applied to Naveris?
A:CareDx plans to apply expertise in provider education, workflow optimization, automation, cost reduction, and Epic integration to Naveris. They will also leverage their customer service team to streamline workflows and support specialty practices.
Q:What is the competitive environment for Naveris, and how will CareDx maintain its niche?
A:Naveris has a differentiated technology that makes it a market leader in HPV-driven cancers. CareDx is confident in sustaining this competitive advantage through its expertise and resources.
Q:What are the financial details of Naveris, including growth rates and drivers?
A:Naveris achieved 75% top-line growth from 2024 to 2025. The projected 30%-40% growth rate is primarily volume-driven, with some contribution from ASP.
Q:What is the market penetration for cell-free DNA testing in transplant, and what is the growth potential?
A:There is significant growth potential as many factions still do not use molecular testing. Kidney, heart, and lung transplants have varying levels of adoption, with lung being in early stages. CareDx sees substantial runway for growth in solid organ transplant.
Q:Does Naveris need a broader portfolio to succeed in its channel?
A:Currently, CareDx is confident in Naveris' portfolio, which is the market leader in head and neck and anal cancers. There is no immediate focus on broadening the portfolio.
Q:Is there any contribution from Naveris included in CareDx's revenue guidance for the year?
A:No, there is no contribution from Naveris included in the revenue guidance for the year.
Q:What is driving ASP improvements in transplant testing, and how does Epic Aura factor in?
A:ASP improvements are driven by better claims submissions and reduced rejections. Epic Aura uplift is not included in the guidance, but automation and revenue cycle management improvements are contributing to higher cash collections per test.
Q:What is the strategy for hematological malignancies MRD with AlloHeme and AlloCell?
A:The strategy is to leverage existing transplant center relationships. The focus for 2027 is on clinical education and early adoption of AlloHeme, building toward Medicare coverage.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines for the GYN cancer indication development at Naveris, stating only that it is still in development. Additionally, they did not provide detailed financial breakdowns for Naveris' 2024 performance or the exact mix of volume versus ASP in the 30%-40% growth projection.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CareDx
HPV
Lab Products
MRD
approach
blood
care
center
context
core
diagnosis
head neck
increase midpoint
indication
insight
kidney
market
model
monitoring
neck cancer
organ transplant
patient
platform
portfolio
precision medicine
product
solution
specialty oncology
study
surveillance
testing service
tissue
transaction
tumor
workflow
CDNA Transcript
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
Positive5-4
The earnings call highlights strong financial growth for Naveris and a strategic focus on expanding testing and improving efficiency, which are positive indicators. The high attach rate for digital solutions at transplant centers and stable reimbursement rates further support a positive outlook. However, some uncertainties, such as the GYN indication timeline and lack of Naveris contribution to current revenue guidance, temper the sentiment slightly. Overall, the positive growth projections and market leadership in key areas suggest a likely positive stock price movement.
CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed picture. Financial performance shows positive trends with increased revenue and net income, but gross margin decline is a concern. The raised revenue and EBITDA guidance are positive, yet the lack of clarity on strategic initiatives and potential risks from forward-looking statements create uncertainty. The absence of a shareholder return plan discussion and unclear management responses in the Q&A further contribute to a neutral sentiment. Without market cap data, the impact on stock price is uncertain, but the mixed signals suggest a neutral movement of -2% to 2%.
Energy Fuels Inc. (EFR:CA) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents a mixed outlook. Positive aspects include the decline in uranium production costs and strong margins, but these are offset by uncertainties in project timelines and vague management responses. The Q&A reveals concerns about strategic decisions and lack of clarity on partnerships. While the convertible note offering boosts liquidity, the lack of acceleration in key projects and unclear guidance tempers enthusiasm. Without a market cap, the overall sentiment remains neutral, anticipating limited stock movement.
CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary reflects a positive outlook with strong financial metrics, optimistic guidance, and strategic initiatives like EPIC integration. Despite some uncertainties, such as the LCD policy impact and transplant volume trends, the company's growth in test volumes, ASP stability, and revenue cycle management victories are encouraging. The Q&A section reinforced confidence in ASP and volume growth, with analysts generally responding positively to management's explanations. The potential $15 million headwind is a reimbursement issue rather than a utilization change, mitigating concerns. Overall, the sentiment is positive, suggesting a 2% to 8% stock price increase.
CDNA Slides
CDNA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
